AbbVie (ABBV): Its Now Time to Get In

     I haven't written about my biopharmaceutical investment, AbbVie Inc. (ABBV), for a while; but I have been following it very closely.  On Friday, it closed at $55.64.  Having bought at $62.62, I only wish I could have gotten in at a lower price.  Great things are going to be done with this company.  My argument is that now is the time to get in.  I list four reasons:

(1) The Dow is off its high.

(2) Many investors sold over the last two trading days because they perceived AbbVie's $21 billion price for Pharmacyclics as too high.  Their money is gone from AbbVie--leaving the company a cheap buy.

(3) The Pharmacyclics acquisition is just the beginning of AbbVie's turnaround of its morale problem that started from the pragmatism of the deal with Express Scripts.

(4) And, then there's the Paul Wharton factor.  The Abbott-AbbVie invention of Depakote saved the quality of my life and literally freed me from a prison-like environment enforced by state governments.  With the gratitude motive (on top of the profit one), investors can expect to see AbbVie (ABBV) getting some boosts from my reading, thinking, and blogging.  I encourage anyone who doubts this to visit my blog: lillyfuel.blogspot.com.  I did all of that in just over a year.

Paul Wharton
Objectivist Capitalist Medicine Promoter